Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 4/20 | 0.35 |
| ▸ | MAP4K2 | Q12851 | 4/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.33 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.33 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.32 |
| ▸ | KIT | P10721 | 2/20 | 0.32 |
| ▸ | FLT3 | P36888 | 2/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.32 |
| ▸ | GAK | O14976 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 4/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.32 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.32 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | INSR | P06213 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270410 | 0.90 | HCAR2 (0.42) | P2RX3HCAR2PLK4PAK4 | |
| SCHEMBL3932730 | 0.88 | HCAR2 (0.31) | HCAR2PLK4PAK4PIK3CAMTOR | |
| SCHEMBL3926810 | 0.87 | MAPT (0.41) | MAP4K2MAP4K4AURKBJAK2RET | |
| SCHEMBL3926096 | 0.83 | MAPK8 (0.45) | JAK2PAK4 | |
| SCHEMBL1268774 | 0.81 | PAK4 (0.48) | IGF1RFLT3PDGFRBSYKAURKB | |
| SCHEMBL1270223 | 0.77 | IGF1R (0.45) | IGF1RAURKBLCKCDK2CCNE2 | |
| SCHEMBL2186457 | 0.77 | PLK4 (0.32) | IGF1RPLK4PAK4 | |
| SCHEMBL2169069 | 0.77 | GRK6 (0.39) | IGF1RAURKAKDRCDK2PLK4 | |
| SCHEMBL1269791 | 0.77 | IGF1R (0.39) | IGF1RBTKPLK4PAK4 | |
| SCHEMBL1269197 | 0.77 | IGF1R (0.38) | IGF1RAURKBAURKALCKCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2041138-B1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8592579-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120302747-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-11-29 | — | — | US | disclosed |
| US-8263765-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110124623-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-26 | — | — | US | disclosed |
| US-7879855-B2 | administering (S)-1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide, for the treatment of cancers of the colon, lung, ovary, and pancreas; anticarcinogenic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090239838-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-24 | — | — | US | disclosed |
| US-7534792-B2 | e.g. 1-(4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)-N-methylpyrrolidine-2-carboxamide; tyrosine kinase inhibitor; anticarcinogenic, antiproliferative agent, neurodegenerative diseases; Alzheimer's disease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-19 | — | — | US | disclosed |
| US-20080009497-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009497-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, STK17A, STK35 | IGF1R 595/4885MAP4K2 14/4885P2RX3 3673/4885 |
| US-20110124623-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, STK17A, STK35 | IGF1R 595/4885MAP4K2 14/4885P2RX3 3673/4885 |
| US-20120302747-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, STK17A, STK35 | IGF1R 595/4885MAP4K2 14/4885P2RX3 3673/4885 |
| US-20090239838-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | STK25, STK17A, STK35 | IGF1R 595/4885MAP4K2 14/4885P2RX3 3673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.